NCT01297777
- Conditions
- Immune System Diseases, Mast Cell Activation Disorders, Mastocytosis, +6 more
- Locations
-
- Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle Toledo, Spain
Clinical trial condition
Mastocytosis, Systemic
Explore clinical trials studying Mastocytosis, Systemic. Study availability and eligibility vary by location and protocol.
37 public trials
7 recruiting studies
Mastocytosis, Systemic trial results
NCT00493129
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
- Locations
-
- The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States
NCT00001760
- Conditions
- Atopic Dermatitis, Behavior, Behavior, Animal, +23 more
- Locations
-
- National Institute of Allergy and Infectious Diseases (NIAID) Bethesda, Maryland, United States
Active, Not Recruiting
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Chronic Disease, +37 more
- Locations
-
- Colorado Blood Cancer Network Denver, Colorado, United States
- University of Maryland, Greenbaum Comprehensive Cancer Center Baltimore, Maryland, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- START - Midwest Grand Rapids, Michigan, United States
Active, Not Recruiting
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753
- Conditions
- BMM, Bone Marrow Mastocytosis, Hematologic Diseases, +15 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Mayo Clinic Arizona Phoenix, Arizona, United States
- One of a Kind Clinical Research Center Scottsdale, Arizona, United States
- Modena Allergy and Asthma Clinical La Jolla, California, United States
Active, Not Recruiting
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT03731260
- Conditions
- Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +6 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Mayo Clinic Hospital Phoenix, Arizona, United States
- Stanford Cancer Institute Stanford, California, United States
- Mayo Clinic Florida Jacksonville, Florida, United States
Active, Not Recruiting
Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis
NCT06065007
- Conditions
- Immune System Diseases, Mast Cell Activation Disorders, Mastocytosis, +5 more
- Locations
-
- Karolinska Institutet Stockholm, Sweden
- Uppsala University Uppsala, Sweden